2022
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan
Mukhatayeva A, Mustafa A, Dzissyuk N, Issanov A, Mukhatayev Z, Bayserkin B, Vermund SH, Ali S. Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan. Scientific Reports 2022, 12: 17195. PMID: 36229577, PMCID: PMC9562405, DOI: 10.1038/s41598-022-22163-7.Peer-Reviewed Original Research
2019
Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART)
Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, Yang B, Phiri M, Schaap A, Eshleman SH, Piwowar-Manning E, Kosloff B, James A, Skalland T, Wilson E, Emel L, Macleod D, Dunbar R, Simwinga M, Makola N, Bond V, Hoddinott G, Moore A, Griffith S, Deshmane Sista N, Vermund SH, El-Sadr W, Burns DN, Hargreaves JR, Hauck K, Fraser C, Shanaube K, Bock P, Beyers N, Ayles H, Fidler S. Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART). New England Journal Of Medicine 2019, 381: 207-218. PMID: 31314965, PMCID: PMC6587177, DOI: 10.1056/nejmoa1814556.Peer-Reviewed Original ResearchConceptsHIV-positive participantsViral suppressionHIV infectionGroup BGroup AGroup CMonth 12Universal testingPrevention interventionsPopulation cohortHuman immunodeficiency virus (HIV) infectionHome-based HIV testingBaseline HIV prevalenceCombination prevention interventionsImmunodeficiency virus infectionHIV-positive adultsPopulation-level incidenceNew HIV infectionsAdjusted rate ratiosCommunity-randomized trialLack of effectHIV carePrevious trial resultsStandard careART adherence
2016
The 2013 HIV Continuum of Care in Tennessee
Wester C, Rebeiro PF, Shavor TJ, Shepherd BE, McGoy SL, Daley B, Morrison M, Vermund SH, Pettit AC. The 2013 HIV Continuum of Care in Tennessee. Public Health Reports 2016, 131: 695-703. PMID: 28123210, PMCID: PMC5230808, DOI: 10.1177/0033354916660082.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAnti-Retroviral AgentsBlack or African AmericanContinuity of Patient CareFemaleHealth Services AccessibilityHealthcare DisparitiesHispanic or LatinoHIV InfectionsHumansMaleMiddle AgedSex FactorsSexual BehaviorSubstance Abuse, IntravenousTennesseeViral LoadYoung AdultConceptsHIV continuumInjection drug usersNon-Hispanic blacksViral suppressionHIV infectionDrug usersHuman immunodeficiency virus (HIV) continuumRyan White ProgramNon-Hispanic black peopleHispanic peopleEnhanced surveillance activitiesPoor outcomeWhite ProgramPatient engagementLaboratory reportingSubgroup disparitiesNashville residentsTennessee residentsCareInfectionSurveillance activitiesVulnerable groupsMenSuppressionResidents
2014
Management of Fever in Ambulatory HIV-Infected Adults in Resource-Limited Settings
Brentlinger PE, Silva WP, Buene M, Morais L, Valverde E, Vermund SH, Moon TD. Management of Fever in Ambulatory HIV-Infected Adults in Resource-Limited Settings. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 67: 304-309. PMID: 25314251, PMCID: PMC5844466, DOI: 10.1097/qai.0000000000000304.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAmbulatory CareAnti-Bacterial AgentsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBacterial InfectionsCD4 Lymphocyte CountDisease ManagementFemaleFeverHIV InfectionsHumansMaleMultivariate AnalysisOutcome Assessment, Health CarePractice Guidelines as TopicProspective StudiesRisk FactorsViral LoadConceptsManagement of feverLow CD4 T-lymphocyte countCD4 T-lymphocyte countLower body mass indexBacterial blood stream infectionsSpecific alternative diagnosesT-lymphocyte countsHistory of feverProspective observational studyBlood stream infectionsBody mass indexResource limited settingsAmbulatory HIVAntiretroviral therapyMalaria testingLower hemoglobinMass indexAdverse outcomesAlternative diagnosesObservational studyAxillary temperatureGuideline performanceMultivariate analysisHIVFeverCurrent drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report
Qian HZ, Mitchell VJ, Bebawy S, Cassell H, Perez G, McGowan CC, Sterling TR, Vermund SH, D’Aquila R, Hulgan T. Current drug use and lack of HIV virologic suppression: point-of-care urine drug screen versus self-report. BMC Infectious Diseases 2014, 14: 508. PMID: 25234368, PMCID: PMC4175271, DOI: 10.1186/1471-2334-14-508.Peer-Reviewed Original ResearchConceptsUrine drug screensCurrent drug usePositive urine drug screenComputer Assisted Self-InterviewVirologic suppressionDrug useAntiretroviral therapyDrug screensNegative urine drug screensHigher CD4 countsHIV disease progressionRoutine clinic visitsHIV virologic suppressionCross-sectional studyLower self-reported ratesSelf-reported ratesCD4 countClinic visitsPrognostic informationDisease progressionCaucasian raceART usersLower likelihoodResultsAbout halfSelf interview
2013
Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China
Liao L, Xing H, Su B, Wang Z, Ruan Y, Wang X, Liu Z, Lu Y, Yang S, Zhao Q, Vermund SH, Chen RY, Shao Y. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. AIDS 2013, 27: 1815-1824. PMID: 23803794, PMCID: PMC3694318, DOI: 10.1097/qad.0b013e3283611931.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyHIV drug resistanceImmunologic failureHigh mortalityVirologic failureAntiretroviral therapyEmergence of HIVDRBaseline CD4 cell countDrug resistanceCD4 cell countCohort of patientsSecond-line drugsEnd of studyProportional hazards modelRural Chinese countiesHIVDR mutationsMedian timePatient adherenceKaplan-MeierChinese patientsRisk factorsHazards modelPatientsCell countMortality
2011
Contemporary profile of oral manifestations of HIV/AIDS and associated risk factors in a southeastern US clinic
Tamí‐Maury I, Willig J, Vermund S, Jolly P, Aban I, Hill J, Wilson CM. Contemporary profile of oral manifestations of HIV/AIDS and associated risk factors in a southeastern US clinic. Journal Of Public Health Dentistry 2011, 71: 257-264. PMID: 22320283, DOI: 10.1111/j.1752-7325.2011.00256.x.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsAntiretroviral Therapy, Highly ActiveBlack or African AmericanCandidiasis, OralCD4 Lymphocyte CountCohort StudiesFemaleFollow-Up StudiesHeterosexualityHIV InfectionsHIV-1Homosexuality, MaleHumansMaleMouth DiseasesOropharynxPharyngeal DiseasesPrevalenceRetrospective StudiesRisk FactorsSex FactorsSoutheastern United StatesViral LoadYoung AdultConceptsOral manifestationsOropharyngeal candidiasisRisk factorsUS clinicsHIV-1 RNA viral loadLow baseline CD4 countBaseline CD4 valueMean baseline CD4Active antiretroviral therapyBaseline CD4 countRNA viral loadHIV-positive individualsHIV/AIDSLogistic regression modelsBaseline CD4Antiretroviral therapyCD4 countLaboratory characteristicsRetrospective reviewCD4 valuesViral loadHIV prevalenceMean ageT cellsHAARTAn addition to the effect of treating co-infections on HIV-1 viral load
Modjarrad K, Vermund SH. An addition to the effect of treating co-infections on HIV-1 viral load. The Lancet Infectious Diseases 2011, 11: 81. PMID: 21272789, DOI: 10.1016/s1473-3099(11)70013-5.Peer-Reviewed Original Research
2010
Effect of treating co-infections on HIV-1 viral load: a systematic review
Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. The Lancet Infectious Diseases 2010, 10: 455-463. PMID: 20610327, PMCID: PMC3071714, DOI: 10.1016/s1473-3099(10)70093-1.Peer-Reviewed Original ResearchConceptsViral load differencesViral loadPlasma HIV-1 RNA concentrationSystematic reviewMean plasma viral loadPlasma HIV RNA concentrationHIV-1 RNA concentrationsHIV-1 viral loadHIV RNA concentrationPlasma viral loadHIV transmission riskViral load reductionNon-pathogenic infectionsCo-infecting pathogensSyphilis treatmentHIV progressionTuberculosis treatmentEligible studiesPopulation-level benefitsTransmission riskLow-income countriesHIVTreatmentInfectionReview
2009
Predictors of Suboptimal Virologic Response to Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Adolescents: Analyses of the Reaching for Excellence in Adolescent Care and Health (REACH) Project
Ding H, Wilson CM, Modjarrad K, McGwin G, Tang J, Vermund SH. Predictors of Suboptimal Virologic Response to Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Adolescents: Analyses of the Reaching for Excellence in Adolescent Care and Health (REACH) Project. JAMA Pediatrics 2009, 163: 1100-1105. PMID: 19996046, PMCID: PMC3739292, DOI: 10.1001/archpediatrics.2009.204.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountChi-Square DistributionFemaleHIV InfectionsHumansInterviews as TopicLogistic ModelsMalePatient CompliancePredictive Value of TestsPrevalenceProspective StudiesStatistics, NonparametricTreatment OutcomeUnited StatesViral LoadYoung AdultConceptsHuman immunodeficiency virus-infected adolescentsSuboptimal virologic responsePoor virologic responseVirologic responseActive antiretroviral therapyAntiretroviral therapyVirologic suppressionMultivariable logistic regression modelDual antiretroviral therapyInitiation of HAARTSuboptimal antiretroviral therapyAge-specific interventionsAcademic medical centerLogistic regression modelsCohort studyLymphocyte countViral loadEcho findingsAdequate adherenceTherapeutic failureBiopsychosocial predictorsHAARTMedical CenterAdolescent careConsecutive visits
2008
Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression
Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008, 22: 2179-2185. PMID: 18832881, PMCID: PMC2661869, DOI: 10.1097/qad.0b013e328312c756.Peer-Reviewed Original ResearchConceptsRisk of progressionHeterosexual transmissionDisease progressionHIV RNALog10 incrementAntiretroviral therapyPlasma HIV RNA levelsGreater riskTreatment of coinfectionHIV RNA levelsHIV viral loadViral load changesHIV-1 RNARelative risk estimatesHIV loadAdjunctive careViral loadPlasma levelsHeterosexual contactWorld's HIVAnnual riskHIVAdult populationViral transmissionRisk estimates
2007
Co-infection with human immunodeficiency virus and tuberculosis in Asia
Vermund SH, Yamamoto N. Co-infection with human immunodeficiency virus and tuberculosis in Asia. Tuberculosis 2007, 87: s18-s25. PMID: 17631414, PMCID: PMC2031213, DOI: 10.1016/j.tube.2007.05.008.Peer-Reviewed Original ResearchConceptsMultiple drug-resistant Mycobacterium tuberculosisDrug-resistant Mycobacterium tuberculosisCo-infected patientsHuman immunodeficiency virusDeath of HIVPublic health workersHIV-tuberculosisHIV seroprevalenceTuberculosis casesImmunodeficiency virusHealth workersTuberculosis accountsPublic health situationMarked riseMycobacterium tuberculosisKey subpopulationsHealth situationTuberculosisResearch prioritiesSalient studiesHigher numberHIVPatientsSeroprevalenceInterdisciplinary collaboration
2005
Treatment of Intestinal Helminths Does Not Reduce Plasma Concentrations of HIV-1 RNA in Coinfected Zambian Adults
Modjarrad K, Zulu I, Redden DT, Njobvu L, Lane HC, Bentwich Z, Vermund SH. Treatment of Intestinal Helminths Does Not Reduce Plasma Concentrations of HIV-1 RNA in Coinfected Zambian Adults. The Journal Of Infectious Diseases 2005, 192: 1277-1283. PMID: 16136473, PMCID: PMC2730764, DOI: 10.1086/444543.Peer-Reviewed Original ResearchConceptsHIV-1 RNAViral loadPlasma concentrationsAntihelminthic treatmentCopies/Helminth infectionsIntestinal helminthsHigh pretreatment viral loadMedian baseline viral loadPretreatment viral loadBaseline viral loadDysfunctional immune responseIntestinal helminth infectionsHuman immunodeficiency virusMean viral loadCopies/mLHigher helminth burdensPosttreatment visitAsymptomatic adultsImmunodeficiency virusProspective studyZambian adultsUninfected groupHIV-1Immune response
2004
Prevention of mother-to-child transmission of HIV in Africa.
Vermund SH. Prevention of mother-to-child transmission of HIV in Africa. Topics In Antiviral Medicine 2004, 12: 130-4. PMID: 15647608.Peer-Reviewed Original ResearchConceptsChild transmissionHIV infectionInternational AIDS Society-USA courseMaternal plasma viral loadExclusive formula feedingNevirapine resistance mutationsSingle-dose nevirapinePrevention of motherPlasma viral loadPerinatal transmission ratePerinatal transmissionAntiretroviral therapyExclusive breastfeedingFormula feedingViral loadMaternal mortalityRisk factorsMortality rateHIVAfrican childrenMixed feedingGreater riskResistance mutationsEarly weaningBreastfeeding
2002
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents
Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, Korber B, Vermund SH, Kaslow RA. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002, 16: 2275-2284. PMID: 12441799, DOI: 10.1097/00002030-200211220-00007.Peer-Reviewed Original ResearchConceptsViral loadHLA class IHost genetic profileHIV-1-infected adolescentsHIV-1-seropositive participantsCD4 T-cell countClass IHIV-seronegative individualsT-cell countsCD4 T lymphocytesHIV-1 infectionHIV-1 pathogenesisGenetic profileClinical patient groupsAntiretroviral therapyQuarterly followMultivariable analysisHealth cohortPatient groupImmunological outcomesImmunological controlNegative HLAT lymphocytesProtective effectAdolescent careCorrelates of Nontransmission in US Women at High Risk of Human Immunodeficiency Virus Type 1 Infection through Sexual Exposure
Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB. Correlates of Nontransmission in US Women at High Risk of Human Immunodeficiency Virus Type 1 Infection through Sexual Exposure. The Journal Of Infectious Diseases 2002, 185: 428-438. PMID: 11865394, PMCID: PMC2743095, DOI: 10.1086/338830.Peer-Reviewed Original ResearchConceptsSexual exposureSuppressive activityHuman immunodeficiency virus type 1 (HIV-1) infectionHigher CD8 cell countsHIV-1-suppressive activitySingle-cell cytokine productionHuman immunodeficiency virus type 1Macrophage inflammatory protein-1 betaVirus type 1 infectionHIV-positive male partnersInflammatory protein-1 betaMale partnersImmunodeficiency virus type 1CD4 cell responseCD8 cell countsHIV-positive donorsHIV-positive partnerHIV-negative partnersType 1 infectionInterferon-gamma secretionHIV-suppressive activityVirus type 1Apparent protective roleHIV antigenLocal antibodies
2001
Virologic and Immunologic Determinants of Heterosexual Transmission of Human Immunodeficiency Virus Type 1 in Africa
Fideli L, Allen S, Musonda R, Trask S, Hahn B, Weiss H, Mulenga J, Kasolo F, Vermund S, Aldrovandi G. Virologic and Immunologic Determinants of Heterosexual Transmission of Human Immunodeficiency Virus Type 1 in Africa. AIDS Research And Human Retroviruses 2001, 17: 901-910. PMID: 11461676, PMCID: PMC2748905, DOI: 10.1089/088922201750290023.Peer-Reviewed Original ResearchConceptsCopies/Heterosexual transmissionRisk ratioMultivariate Cox regression analysisHuman immunodeficiency virus type 1Immunodeficiency virus type 1Plasma viral loadCox regression analysisCorresponding risk ratioHIV-1 RNAVirus type 1Female transmissionCase-control designGender-specific differencesPlasma VLImmunologic correlatesViral loadProspective studySerology resultsWorld's HIVVirus isolationType 1Immunologic determinantsReference groupNontransmitters
1998
Serum Retinol and HIV-1 RNA Viral Load in Rapid and Slow Progressors
Camp W, Allen S, Alvarez J, Jolly P, Weiss H, Phillips J, Karita E, Serufilira A, Vermund S. Serum Retinol and HIV-1 RNA Viral Load in Rapid and Slow Progressors. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 401-406. PMID: 9704954, DOI: 10.1097/00042560-199808010-00022.Peer-Reviewed Original ResearchConceptsSerum retinol levelsHIV-1 RNA viral loadLow viral loadLow serum retinol levelsRNA viral loadSlow progressorsRetinol levelsViral loadHIV serologySerum retinolDisease progressionFirst HIV-positive testHigher serum retinol levelsAsymptomatic HIV infectionHigh HIV loadLow serum retinolSerum retinol valuesHIV disease progressionHIV-positive testHigh viral loadThirty HIVHIV loadHIV infectionRapid progressorsSerum vitaminSerum Retinol and HIV-1 RNA Viral Load in Rapid and Slow Progressors
Camp W, Allen S, Alvarez J, Jolly P, Weiss H, Phillips J, Karita E, Serufilira A, Vermund S. Serum Retinol and HIV-1 RNA Viral Load in Rapid and Slow Progressors. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 21-26. PMID: 9593454, DOI: 10.1097/00042560-199805010-00004.Peer-Reviewed Original ResearchConceptsSerum retinol levelsLow viral loadHIV-1 RNA viral loadLow serum retinol levelsRNA viral loadSlow progressorsRetinol levelsViral loadHIV serologySerum retinolDisease progressionFirst HIV-positive testHigher serum retinol levelsAsymptomatic HIV infectionHigh HIV loadLow serum retinolSerum retinol valuesHIV disease progressionHIV-positive testHigh viral loadThirty HIVHIV loadHIV infectionRapid progressorsSerum vitaminAnalysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines
Graham B, McElrath M, Connor R, Schwartz D, Gorse G, Keefer M, Mulligan M, Matthews T, Wolinsky S, Montefiori D, Vermund S, Lambert J, Corey L, Belshe R, Dolin R, Wright P, Korber B, Wolff M, Fast P, Group A. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines. The Journal Of Infectious Diseases 1998, 177: 310-309. PMID: 9466516, DOI: 10.1086/514209.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS VaccinesAmino Acid SequenceCD4 Lymphocyte CountFemaleHIV AntibodiesHIV Envelope Protein gp120HIV InfectionsHIV-1HumansImmunity, ActiveIncidenceMaleMiddle AgedMolecular Sequence DataNeutralization TestsPeptide FragmentsRisk-TakingSequence AnalysisSubstance Abuse, IntravenousViral LoadConceptsHIV-1 infectionHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionCandidate AIDS vaccinesType 1 infectionAIDS vaccinePhase IHigh-risk sexual exposureVaccine-induced immune responsesComplete immunization scheduleEarly clinical courseCD4 lymphocyte countIntravenous drug useV3 loop amino acid sequencesUninfected subjectsVaccine recipientsLymphocyte countClinical courseImmunization scheduleSexual exposureVirus loadImmune responseControl groupDrug useInfection